Literature DB >> 15122521

Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort.

Jeffrey J Post1, Yong Pan, Anthony J Freeman, Charles E Harvey, Peter A White, Patricia Palladinetti, Paul S Haber, George Marinos, Michael H Levy, John M Kaldor, Kate A Dolan, Rosemary A Ffrench, Andrew R Lloyd, William D Rawlinson.   

Abstract

Understanding the earliest virological and immunological events in acute hepatitis C virus (HCV) infection may provide insight into the determinants of protective immunity. Four cases of HCV viremia with subsequent viral clearance, but without biochemical hepatitis or anti-HCV seroconversion, are reported from a prospective cohort study of prison inmates. Two of the subjects who developed sustained viremia were assessed for production of interferon (IFN)- gamma, by use of the enzyme-linked immunospot (ELISPOT) method and by assessment of HCV cytotoxic T lymphocyte (CTL) activity, CD4 lymphocyte proliferative responses, HCV load, and genotype. After 2-6 months of viremia, all 4 subjects cleared serum HCV RNA. Specific cellular responses were detected in both of the subjects who were assessed, and production of IFN- gamma was demonstrated in one subject. All subjects had weak, but consistent, serological reactivity against HCV nonstructural proteins on immunoblot testing, despite repeatedly nonreactive HCV ELISA tests. These cases highlight the potential for cellular immune responses against HCV to facilitate viral clearance, responses that may model those required for effective HCV vaccination.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122521     DOI: 10.1086/383279

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  48 in total

1.  Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected].

Authors:  Krystle A Lang Kuhs; Arielle A Ginsberg; Jian Yan; Roger W Wiseman; Amir S Khan; Niranjan Y Sardesai; David H O'Connor; David B Weiner
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

Review 2.  Acute hepatitis C virus infection: a chronic problem.

Authors:  Jason T Blackard; M Tarek Shata; Norah J Shire; Kenneth E Sherman
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

Review 3.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

4.  Hepatitis C virus-multispecific T-cell responses without viremia or seroconversion among Egyptian health care workers at high risk of infection.

Authors:  Sayed F Abdelwahab; Zainab Zakaria; Maha Sobhy; Eman Rewisha; Mohamed A Mahmoud; Mahmoud A Amer; Mariarosaria Del Sorbo; Stefania Capone; Alfredo Nicosia; Antonella Folgori; Mohamed Hashem; Samer S El-Kamary
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

Review 5.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

6.  New perspectives in occult hepatitis C virus infection.

Authors:  Vicente Carreño; Javier Bartolomé; Inmaculada Castillo; Juan Antonio Quiroga
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

7.  Loss of virus-specific T-cell responses in HCV exposed uninfected injection drug users with drug rehabilitation.

Authors:  Prem H Thurairajah; Doha Hegazy; Andrew Demaine; Edward R Kaminski; Matthew E Cramp
Journal:  J Infect Dis       Date:  2011-03-15       Impact factor: 5.226

8.  Cellular immune responses associated with occult hepatitis C virus infection of the liver.

Authors:  Juan A Quiroga; Silvia Llorente; Inmaculada Castillo; Elena Rodríguez-Iñigo; Margarita Pardo; Vicente Carreño
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

9.  Risk factors for hepatitis C infection and perception of antibody status among male prison inmates in the Hepatitis C Incidence and Transmission in Prisons Study cohort, Australia.

Authors:  Jennifer A Gates; Jeffrey J Post; John M Kaldor; Yong Pan; Paul S Haber; Andrew R Lloyd; Kate A Dolan
Journal:  J Urban Health       Date:  2004-09       Impact factor: 3.671

10.  Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.

Authors:  Krystle A Lang; Jian Yan; Ruxandra Draghia-Akli; Amir Khan; David B Weiner
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.